Concepedia

Gordon Moody

GM

17

Publications

1.7K

Citations

15

H-Index

1989

Active since

Affiliations

Amgen (United States)(Current)

Amgen (Germany)

AstraZeneca (Netherlands)

Human Genome Sciences (United States)

Gordon Moody is an author at Amgen (United States) specializing in medicine, cell biology, and cancer research.

Top concepts

Publications per year

1989–2023

17

Publications

17

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Sean Caenepeel, Sean P. Brown, Brian Belmontes et al. · Cancer Discovery · 2018 · 408 citations · Full text

Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models

Pedro J. Beltran, Patricia L. Mitchell, Gordon Moody et al. · Journal of Clinical Oncology · 2008 · 235 citations

, , +20

Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment

Susannah L. Hewitt, D. R. Shackleton Bailey, John Zielinski et al. · Clinical Cancer Research · 2020 · 206 citations · Full text

Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys

Blaire L. Osborn, Henrik S. Olsen, Bernardetta Nardelli et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 193 citations

Molecular Mechanism of Hepcidin-Mediated Ferroportin Internalization Requires Ferroportin Lysines, Not Tyrosines or JAK-STAT

Sandra L. Ross, Lynn Tran, Aaron Winters et al. · Cell Metabolism · 2012 · 140 citations · Full text

, , +6

Rows per page

1–5 of 17